AccurEdit Therapeutics raises $75M Series A for CRISPR medicines, reports promising data in ATTR and PCSK9 programs. CEO Yongzhong Wang leads development of gene therapies in China.

AccurEdit Therapeutics raises $75M Series A for CRISPR medicines, reports promising data in ATTR and PCSK9 programs. CEO Yongzhong Wang leads development of gene therapies in China.

AccurEdit Therapeutics raises $75M Series A for CRISPR medicines, reports promising data in ATTR and PCSK9 programs. CEO Yongzhong Wang leads development of gene therapies in China.

AccurEdit Therapeutics announced ART001, China's first gene editing therapy, received FDA RMAT designation, expediting its clinical development.

AccurEdit Therapeutics will showcase its innovative abstracts at the 2025 ASGCT, highlighting advances in gene editing technology and its pivotal ART001 therapy.

CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). ART001, which utilizes lipid nanoparticle (LNP)...

AccurEdit Therapeutics, a startup based in Suzhou, China, has raised $75 million in Series A funding to advance its growing pipeline of CRISPR-based medicines — among the largest rounds on record for a Chinese gene editing ...

AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation  PR Newswire

YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences demonstrates encouraging initial clinical data for...